- Home
- REGN vs APD Comparison
REGN vs APD Comparison
Compare REGN & APD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- APD
- Stock Information
- Founded
- REGN 1988
- APD 1940
- Country
- REGN United States
- APD United States
- Employees
- REGN N/A
- APD N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- APD Major Chemicals
- Sector
- REGN Health Care
- APD Industrials
- Exchange
- REGN Nasdaq
- APD Nasdaq
- Market Cap
- REGN 59.5B
- APD 64.1B
- IPO Year
- REGN 1991
- APD 1987
- Fundamental
- Price
- REGN $589.48
- APD $299.36
- Analyst Decision
- REGN Buy
- APD Buy
- Analyst Count
- REGN 22
- APD 15
- Target Price
- REGN $806.32
- APD $333.93
- AVG Volume (30 Days)
- REGN 1.0M
- APD 917.3K
- Earning Date
- REGN 08-01-2025
- APD 07-31-2025
- Dividend Yield
- REGN 0.60%
- APD 2.39%
- EPS Growth
- REGN 5.03
- APD N/A
- EPS
- REGN 39.67
- APD 6.95
- Revenue
- REGN $14,214,200,000.00
- APD $12,057,900,000.00
- Revenue This Year
- REGN N/A
- APD $0.09
- Revenue Next Year
- REGN $6.65
- APD $4.90
- P/E Ratio
- REGN $14.86
- APD $43.03
- Revenue Growth
- REGN 5.38
- APD N/A
- 52 Week Low
- REGN $476.49
- APD $243.69
- 52 Week High
- REGN $1,211.20
- APD $341.14
- Technical
- Relative Strength Index (RSI)
- REGN 60.67
- APD 61.21
- Support Level
- REGN $570.39
- APD $287.11
- Resistance Level
- REGN $585.00
- APD $294.39
- Average True Range (ATR)
- REGN 16.72
- APD 4.72
- MACD
- REGN 2.93
- APD 0.59
- Stochastic Oscillator
- REGN 68.39
- APD 91.42
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About APD Air Products and Chemicals Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $12.1 billion in revenue in fiscal 2024.